EMA streamlines procedures amid "challenging" economic climate
This article was originally published in Scrip
Faced with budget constraints and an ever-growing workload, the European Medicines Agency is reorganizing its internal processes in a bid to make them more efficient while increasing the overall quality of its work. The move includes the creation of two new senior positions to allow individual products to be more closely shepherded through the EMA drug evaluation process.
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.